Genenta Science SPA (Genenta Science SPA) Debt-to-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Genenta Science SPA Debt-to-Asset?

Genenta Science SPA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Genenta Science SPA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Genenta Science SPA's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $24.37 Mil. Genenta Science SPA's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Genenta Science SPA Debt-to-Asset Historical Data

The historical data trend for Genenta Science SPA's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genenta Science SPA Debt-to-Asset Chart

Genenta Science SPA Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Genenta Science SPA Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Genenta Science SPA's Debt-to-Asset

For the Biotechnology subindustry, Genenta Science SPA's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genenta Science SPA's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genenta Science SPA's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Genenta Science SPA's Debt-to-Asset falls into.

Genenta Science SPA Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Genenta Science SPA's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	24.37
	=	0.00

Genenta Science SPA's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	24.37
	=	0.00

Genenta Science SPA (NAS:GNTA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Genenta Science SPA Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Genenta Science SPA's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genenta Science SPA (Genenta Science SPA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genenta Science SPA (NAS:GNTA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

K5F:Germany

Address

Via Olgettina No. 58, Milan, ITA, 20132

Website

https://www.genenta.com

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's lead product includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.